These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18590011)

  • 1. [National economic consequences of vaccines].
    Bergman A; Persson U
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1680-4. PubMed ID: 18590011
    [No Abstract]   [Full Text] [Related]  

  • 2. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
    Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
    Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling the costs and effects of a universal infant immunization program using conjugated pneumococcal vaccine in British Columbia.
    Moore D; Bigham M; Patrick D
    Can Commun Dis Rep; 2003 Jun; 29(11):97-104. PubMed ID: 12794969
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost-effectiveness analysis of a universal vaccination programme with the 7-valent pneumococcal conjugate vaccine (PCV-7) in Sweden.
    Bergman A; Hjelmgren J; Ortqvist A; Wisløff T; Kristiansen IS; Högberg LD; Persson KM; Persson U
    Scand J Infect Dis; 2008; 40(9):721-9. PubMed ID: 18712627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of a 3-dose pneumococcal conjugate vaccine program in the province of Quebec, Canada.
    Poirier B; De Wals P; Petit G; Erickson LJ; Pépin J
    Vaccine; 2009 Nov; 27(50):7105-9. PubMed ID: 19786137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vaccination--value for money?].
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Kristiansen IS
    Tidsskr Nor Laegeforen; 2006 Oct; 126(20):2670-3. PubMed ID: 17057767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New vaccines against otitis media: projected benefits and cost-effectiveness.
    O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
    Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The heptavalent conjugate pneumococcal vaccine and its implications for managed care--clinical overview and roundtable discussions.
    Alexander PG; Chartrand SA; Davies TJ; Gaines BM; Oster G; Shurin P; Tamsky L; Thornton DK; Wittert W
    Manag Care Interface; 2001; Suppl C():10-28; quiz 29-30. PubMed ID: 11724029
    [No Abstract]   [Full Text] [Related]  

  • 10. [Vaccination of the elderly against pneumococcal disease is cost-efficient. Mass vaccination of all aged 65 and over is recommended].
    Ortqvist A; Jönsson B; Baltussen R; Ament A
    Lakartidningen; 2000 Nov; 97(45):5120-5. PubMed ID: 11116891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic evaluation of pneumococcal conjugate vaccination in Finland.
    Salo H; Sintonen H; Nuorti JP; Linna M; Nohynek H; Verho J; Kilpi T
    Scand J Infect Dis; 2005; 37(11-12):821-32. PubMed ID: 16308215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of stockpiling 23-valent pneumococcal polysaccharide vaccine to prevent secondary pneumococcal infections among a high-risk population in the United States during an influenza pandemic.
    Dhankhar P; Grabenstein JD; O'Brien MA; Dasbach EJ
    Clin Ther; 2010 Aug; 32(8):1501-16. PubMed ID: 20728763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Challenges in cost-effectiveness analyses of hospital interventions to improve quality.
    Davis MM
    Infect Control Hosp Epidemiol; 2008 May; 29(5):395-7. PubMed ID: 18419359
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-utility analysis of patient care in children with meningeal signs.
    Oostenbrink R; Oostenbrink JB; Moons KG; Derksen-Lubsen G; Essink-Bot ML; Grobbee DE; Redekop WK; Moll HA
    Int J Technol Assess Health Care; 2002; 18(3):485-96. PubMed ID: 12391942
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-burden of paediatric pneumococcal disease in Sweden and the potential cost-effectiveness of prevention using 7-valent pneumococcal vaccine.
    Silfverdal SA; Berg S; Hemlin C; Jokinen I
    Vaccine; 2009 Mar; 27(10):1601-8. PubMed ID: 19146905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of the pneumococcal vaccine in the United States Navy and Marine Corps.
    Vold Pepper P; Owens DK
    Clin Infect Dis; 2000 Jan; 30(1):157-64. PubMed ID: 10619745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of universal pneumococcal vaccination for infants in Italy.
    Lucioni C; Mazzi S
    Vaccine; 2006 Mar; 24(11):1735. PubMed ID: 16356601
    [No Abstract]   [Full Text] [Related]  

  • 18. [New vaccines to be considered in pediatrics and school health services].
    Trollfors B
    Lakartidningen; 2008 May 28-Jun 3; 105(22):1660-4. PubMed ID: 18590007
    [No Abstract]   [Full Text] [Related]  

  • 19. [Pneumococcal vaccine for the elderly--ineffective but cost-efficient?].
    Håkansson J
    Lakartidningen; 2000 Dec; 97(50):5958. PubMed ID: 11188544
    [No Abstract]   [Full Text] [Related]  

  • 20. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
    Claes C; Reinert RR; von der Schulenburg JM
    Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.